Comparison · NCT03252353-2dbee035
Octreotide Capsules vs Placebo: Number of Patients Who Begin Rescue Treatment
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Octreotide Capsules vs Placebo: Number of Patients Who Begin Rescue Treatment. Trial comparisons, record NCT03252353-2dbee035. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03252353-2dbee035
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.25 | 0.127 | 0.434 | wilson | |
| Risk in group 2 | 0.679 | 0.493 | 0.821 | wilson | |
| Risk difference, group 1 minus group 2 | -0.429 | -0.617 | -0.168 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.368 | 0.185 | 0.735 | log | |
| Odds ratio, group 1 over group 2 | 0.158 | 0.0492 | 0.507 | log | |
| Number needed to treat, for one fewer participant with the outcome on Octreotide Capsules than on Placebo | 2.33 | 1.62 | 5.96 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Octreotide Capsules | Octreotide capsules 40 mg/day, 60 mg/day, 80 mg/day (individual dose titration) | 7 | 28 | OG000 |
| Group 2 | Placebo | Matching placebo | 19 | 28 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Patients Who Begin Rescue Treatment
- Description
- Number of Patients who Began Rescue Treatment Prior to and Including Week 36
- Time frame
- Week 36
- Population
- The number of patients who began rescue treatment
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
- NCT number
- NCT03252353
- Phases
- PHASE3
- Conditions
- Acromegaly
- Interventions
- octreotide capsules, Matching placebo
- Lead sponsor
- Chiasma, Inc.
- Results first posted
- 2020-10-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03252353?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03252353-2dbee035